Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
V180 + ISCOMATRIX
- Development stage
- Phase 1
- Lead developer
- Merck
- Modality
- Nanoparticles → Drug Delivery Systems, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**V180 + ISCOMATRIX is an investigational recombinant tetravalent dengue vaccine formulation.** - The vaccine consists of truncated envelope proteins (DEN-80E) from all four dengue virus serotypes as antigens. - It is adjuvanted with ISCOMATRIX, a saponin-based nanoparticle adjuvant known to enhance both humoral and cellular immune responses by promoting antigen delivery and presentation and stimulating CD4+ and CD8+ T cell responses[2][3][4][6][7]. - Developed by Merck & Co., the combination was evaluated in Phase I clinical trials in flavivirus-naïve adults. Six different formulations containing the ISCOMATRIX adjuvant demonstrated robust immunogenicity, with seroconversion rates exceeding 85% for all four dengue serotypes after three doses[3][6][7]. - The addition of the ISCOMATRIX adjuvant resulted in higher frequencies of injection-site adverse events compared to aluminum-adjuvanted or unadjuvanted formulations but was generally well tolerated overall[6][7]. - The primary indication is prevention of dengue infection.
- Other names
- TetraVax-DVTetraVax-DV (V180) + ISCOMATRIX
02
Targets
TCR-DENV-E (T-cell receptor recognizing dengue virus envelope protein-derived peptides)BCR (Immunoglobulin G B Cell Receptor)
Beyond the preview
Go deeper on V180 + ISCOMATRIX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on V180 + ISCOMATRIX.